Executive Summary

On May 29, 2026, the U.S. Food and Drug Administration (FDA) approved MannKind’s Afrezza® (insulin human) inhalation powder for use in children and adolescents aged 6 and older with diabetes (type 1 or type 2) (^[1]) (^[2]). Afrezza is a rapid-acting, inhaled insulin developed on MannKind’s Technosphere® platform that mimics physiologic insulin action with an ultra-fast onset and short duration (^[3]) (^[4]). This marks the first FDA-approved inhaled insulin for pediatric patients and adds a novel, needle-free prandial insulin option to the pediatric diabetes armamentarium (^[1]) (^[5]). The approval was based on the pivotal INHALE-1 clinical trial and related safety data (^[6]) (^[7]). INHALE-1 (NCT04974528) enrolled 230 children (ages 4–17) with diabetes (98% type 1, 2% type 2) on multiple daily injections (MDI) and randomized them 1:1 to inhaled Afrezza or injectable rapid-acting insulin analogs (lispro, aspart, or glulisine), each combined with basal insulin (^[7]). After 26 weeks, Afrezza’s efficacy (HbA1c change) narrowly missed the pre-specified noninferiority margin relative to injected analogues (^[8]). Nevertheless, Afrezza exhibited a comparable safety profile (no significant differences in severe hypoglycemia or lung function changes) and yielded secondary benefits such as higher treatment satisfaction and less weight gain compared to injections (^[9]). Based on this evidence and decades of prior data, the FDA recognized Afrezza as a “new inhaled mealtime insulin option” in the FDA’s updated labeling (^[10]) (^[6]).

The pediatric approval of Afrezza has far-reaching implications. Children with diabetes and their families have historically managed insulin via injections or pumps, often with burdens of planning, needle-phobia, and lifestyle intrusion. Inhaled Afrezza enables insulin dosing at the start of a meal without needles, offering flexibility for children in school or during sports (^[10]) (^[11]). Clinical experts and caregivers anticipate that this option will “fit the realities of daily life” and ease mealtime management (^[11]) (^[12]). The American Diabetes Association’s 2026 Standards of Care now recognize inhaled insulin alongside injectable mealtime insulins and pumps as an alternate strategy for prandial glucose control in children (^[10]).

From a market perspective, this approval opens a new frontier in the pediatric diabetes device market. The global pediatric diabetes management market was about $5.6 billion in 2024 and is projected to grow rapidly (~10% CAGR) to over $13 billion by 2033 (^[13]). Within this market, insulin delivery systems (pumps, pens, syringes) and glucose monitoring dominate share, with continuous glucose monitors (CGMs) alone accounting for ~34% of revenue (^[14]). Experts project that even a small penetration of inhaled insulin could represent substantial revenue: MannKind estimates that “every 10% pediatric market share is ~$150M in annual revenue” (^[15]), implying multi-hundred-million-dollar opportunity at scale. The company’s internal analysis predicted that 28% of children on injections and 14% on pump therapy might switch to Afrezza (^[16]). In summary, the Afrezza pediatric approval introduces an innovative insulin delivery modality for youth, with expected clinical and quality-of-life benefits. Its impact on diabetes care and the diabetes device industry will unfold over the coming years, as clinicians gain experience and as Afrezza adoption patterns emerge among families and payers.

Introduction and Background

Diabetes mellitus in children and adolescents is a growing public health concern. The majority (~90%) of pediatric diabetes is type 1 (T1D), an autoimmune insulin deficiency, but type 2 diabetes (T2D) is increasing in youth due to rising obesity and sedentary lifestyles (^[17]) (^[18]). In the United States, landmark SEARCH for Diabetes in Youth data (2017) estimated T1D prevalence at ~2.15 per 1,000 children (ages 0–19) and T2D at ~0.67 per 1,000 (ages 10–19) (^[19]). This reflects roughly 7,759 youth with T1D and 1,230 with T2D in 2017 in representative regions of the US. Notably, T2D prevalence is much higher in minority youth – for example, 1.8/1000 in Black vs. 0.2/1000 in non-Hispanic White youth (^[20]). Epidemiological studies show that both types are rising: from 2001 to 2017, pediatric T1D prevalence increased ~45% and T2D increased ~95% (though T2D started from a smaller baseline) (^[21]). Globally, pediatric diabetes rates are rising similarly, particularly in developing regions, adding urgency to expand treatment options.

Management of pediatric diabetes is challenging. In T1D, exogenous insulin is essential. Traditionally, children have relied on multiple daily subcutaneous injections (MDI) of basal and rapid-acting insulin, or on continuous subcutaneous infusion (CSI) via insulin pumps (^[22]) (^[23]). Both approaches have drawbacks.MDI requires children (or caregivers) to inject insulin at meal times, demanding coordination and carbohydrate counting. Pumps offer automated basal insulin delivery and bolus doses but involve tethered or patch devices that some children find cumbersome, and require wearing an infusion set. Moreover, hypoglycemia risk, weight gain, and variable absorption remain concerns with injected insulin. Type 2 pediatric patients, though fewer, may also require insulin for glycemic control, especially as disease progresses.

Over the past two decades, diabetes care technology has rapidly evolved. Continuous glucose monitoring (CGM) devices have transformed monitoring; major CGM systems (Dexcom G7, Medtronic Guardian, Abbott FreeStyle Libre) are now approved for very young children (e.g. G7 for ages ≥2 (^[24])) and enable real-time tracking. Automated insulin delivery (AID) or “artificial pancreas” systems combine CGM with pumps and algorithms (e.g. Tandem Control-IQ, Medtronic 670G/780G, Omnipod 5) to adjust insulin and reduce workload. New insulin pump approvals (e.g. Tandem’s Mobi mini-pump for ages ≥6 (^[25]), Abbott’s portable AID) continue to reshape therapy. However, the prandial insulin dose remains primarily delivered via subcutaneous route (either with boluses from syringes/pens or via pump), which is burdensome. Children often dislike injections, which can lead to non-adherence: one study found that up to 30% of pediatric patients missed recommended meal insulin doses (^[26]). Psychosocial factors (needle fear, stigma, disruption of activities) contribute to adherence issues and suboptimal control (^[26]).

In this context, alternative delivery methods have long been sought. Inhalable insulin is one such approach. The lungs offer a large surface area (roughly a tennis court) and rapid systemic uptake (^[27]). Technosphere® insulin (Afrezza) is a dry powder formulation of human insulin designed to be inhaled with an ultrafine particle aerosol. Pharmacokinetic studies have shown that inhaled Technosphere insulin (TI) reaches peak blood levels much faster than injected insulin – on the order of 10–15 minutes (vs. 45–60 minutes for subcutaneous analogues) – with a short duration (concentration nearly returning to baseline by 120–180 minutes) (^[3]) (^[4]). These properties theoretically allow insulin to more closely match the body’s natural rapid insulin spike after eating.

The idea of inhaled insulin dates back nearly a century, with initial concept studies in the 1920s and 1930s (^[4]). The first FDA-approved inhaled insulin was Pfizer’s Exubera (2006), a dry-powder insulin delivered by a large portable inhaler (^[4]). Exubera’s approval was short-lived: it was withdrawn in 2007 due to virtually no market uptake (^[28]) (^[4]). Analysts attributed this to its bulky inhaler device, required routine lung function testing, high cost, and the lack of a compelling clinical advantage over injections (^[29]) (^[4]). For example, Exubera’s global sales were only $4 million in Q2 2007 (^[28]) despite heavy marketing efforts. Many physicians and insurers saw inhaled insulin as offering convenience without sufficient benefit to justify higher price or hassle (^[29]).

MannKind’s Afrezza represents a second-generation inhaled insulin. Approved in adults in 2014, Afrezza uses the Technosphere platform (fumaryl diketopiperazine particles) to rapidly deliver insulin via a compact inhaler (^[4]) (^[23]). In clinical use in adults, Afrezza has demonstrated similar A1C reductions to injected analogs while causing less post-prandial hypoglycemia and weight gain in some studies (^[30]) (^[31]). However, as of 2026 it had been approved only for adults (≥18 years), with mandated baseline pulmonary function testing due to asthma/COPD contraindications (^[2]) (^[32]). The May 2026 pediatric labeling expansion finally enables Afrezza use in children 6+, based on the INHALE-1 trial and long-term inhaled insulin data.

This report analyzes multiple facets of the Afrezza pediatric approval: the clinical evidence and regulatory path, the significance for patients and clinicians, and the implications for the pediatric diabetes device market. We examine epidemiological data on pediatric diabetes, compare inhaled insulin to existing therapies, and review market trends. Expert commentary and caregiver perspectives are incorporated, as well as example scenarios of potential use. Data from published studies, regulatory documents, industry reports, and ADA guidelines are cited throughout to substantiate claims. This comprehensive analysis aims to illuminate how the introduction of inhaled insulin for children will affect clinical practice and market dynamics in pediatric diabetes care.

The Inhaled Insulin Technology: Mechanism and History

Inhaled insulin works by converting insulin (usually regular human insulin) into an ultrafine powder that can be aerosolized and deposited into the lungs, where it rapidly enters the bloodstream. Afrezza’s specific formulation involves insulin adsorbed onto fumaryl diketopiperazine (FDKP) microparticles. When a patient inhales from the single-use DPI (dry powder inhaler), the powder is drawn deep into the alveoli. The Technosphere particles then dissolve at physiologic pH, releasing insulin that crosses into capillaries (^[33]). Unique to this platform, the FDKP carrier dissolves and is excreted without metabolic impact (^[34]). This yields very fast absorption: Afrezza attains peak plasma insulin in ~10–15 minutes after inhalation and is largely cleared by about 2–3 hours (^[3]). For comparison, rapid-acting injectable analogs (lispro, aspart, glulisine) typically peak at ~45–60 minutes and take 4–5 hours to return to baseline (^[3]). In practical terms, Afrezza’s profile means it starts lowering glucose sooner and ends sooner than injectable boluses.

Table 1 (below) summarizes key pharmacokinetic differences among prandial insulin options and typical administration modalities.

Table 1. Comparative properties of prandial insulin delivery methods in pediatric diabetes.

The literature also highlights important nuances. For example, Haller et al. note that Afrezza’s rapid profile can reduce late post-meal glucose spikes (“excursions”), potentially leading to better overall control of postprandial hyperglycemia (^[3]). Afrezza’s quick dissipation also means less insulin tailing, which can reduce risk of late hypoglycemia and reduce “insulin stacking” when multiple meals are eaten close together. This is one aspect pediatric endocrinologists have praised. One pediatric specialist noted with regard to inhaled insulin: “The lack of insulin stacking is appealing…” (^[36]), meaning that unused insulin from a previous dose does not linger dangerously long in the body.

Historically, inhaled insulin has not been widely adopted in pediatrics. The only former approved product, Exubera (2006), was never approved for children under 18 (^[37]). Clinical trials of Exubera in youth (2005–2007) did find that minor lung volume declines occurred, but overall pediatric lung growth was not affected by 24 weeks of use (^[38]). Children did experience more cough with Exubera than injection (31% vs 9%) (^[39]). Yet Exubera’s cumbersome inhaler (nearly the size of a small coffee thermos), mandatory spirometry every 6 months, and high price led to disuse (^[29]) (^[4]). Thus, despite theoretical benefits, physicians remained cautious. A 2020 review notes that although many inhalers exist, “they have not been widely recommended for application in children” due to technical challenges and side effects (^[40]).

Afrezza’s inhaler is much smaller (about the size of a pack of gum) and is intended for daily portability. Nevertheless, safety remains a concern: inhaled insulin carries a boxed warning for bronchospasm risk, and it is contraindicated in pediatric patients with any chronic lung disease (such as asthma or cystic fibrosis) (^[41]) (^[32]). In clinical practice, children starting Afrezza must undergo baseline spirometry, and periodic lung testing is recommended. (^[41]) (^[32]). The long-term pulmonary effects in youth beyond 26 weeks are not fully known, though short-term data is reassuring (^[42]) (^[38]). Nonetheless, the inhaled route opens an attractive avenue for needle-averse patients and those who struggle with injection-based dosing.

Clinical Trial Evidence Supporting Pediatric Use

The pediatric approval of Afrezza is grounded chiefly in the results of the INHALE-1 Phase 3 trial. INHALE-1 (NCT04974528) was a randomized, open-label, head-to-head trial that compared Afrezza to standard injectable rapid-acting insulin analogs (insulin aspart, lispro, or glulisine), both regimens combined with a patient’s usual long-acting basal insulin and continuous glucose monitoring (CGM) (^[43]) (^[7]). The trial included 230 children and adolescents (mean age ~12) who had T1D (98%) or T2D (2%) and an initial HbA1c between 7.0% and 11.0% (^[43]) (^[7]). Participants were randomized 1:1 to use Afrezza inhalations at mealtime (dosed to match carbohydrate intake) or to pre-meal injection of a standard analog, for 26 weeks. After 26 weeks, all participants entered an open-label extension through 52 weeks in which everyone received Afrezza, allowing for long-term safety evaluation (^[44]) (^[7]).

The primary efficacy endpoint was the change in HbA1c from baseline to 26 weeks, testing noninferiority with a margin of 0.4% (^[7]). INHALE-1 results, published in Diabetes Care, showed that Afrezza did not quite meet the pre-specified noninferiority criterion for HbA1c. At 26 weeks, the mean ± SD HbA1c was 8.22%±0.87 at baseline and 8.41%±1.38 on Afrezza, versus 8.21%±0.96 to 8.21%±1.10 on injection (^[45]). The adjusted difference was +0.18% (95% CI –0.07, 0.43) in favor of injections; equivalence testing yielded a non-inferiority p=0.091 (above typical alpha) (^[45]). This indicates a trend (18 hub points difference) but not definitive.

Importantly, many secondary measures showed comparable or favorable trends. Glycemic Time-in-Range (CGM TIR, 70–180 mg/dL) did not significantly differ between groups (–2.2% point difference, P=0.38) (^[45]). Adverse event (AE) rates were similar: severe hypoglycemia occurred in 2 Afrezza patients vs 1 on injection over 26 weeks (^[46]). Crucially for pediatric use, there was no significant lung safety signal. Forced Expiratory Volume in 1 second (FEV₁) change from baseline to week 26 was essentially identical between Afrezza and injected groups (no significant difference, P=0.53) (^[47]). In fact, “the treatment difference in FEV₁ decline was clinically negligible,” supporting inhaled insulin’s lung tolerability in youth (consistent with adult findings). There were no new safety concerns beyond the known risks of inhaled insulin (cough, throat irritation, low-frequency bronchospasm) (^[48]) (^[38]).

Patient-reported outcomes (PROs) provided further insight. The Afrezza group reported significantly higher satisfaction with their mealtime insulin (p=0.004), reflecting preferences for the inhaler’s convenience (^[47]). Also notable, children on Afrezza gained significantly less weight (and BMI percentile) over 6 months than those on injections (p=0.009) (^[47]) – a clinically meaningful advantage given concerns about weight gain with insulin therapy. The authors concluded that “TI [Technosphere Insulin] use was safe over 26 weeks…with greater treatment satisfaction and less weight gain…supporting TI as a treatment option for some pediatric patients with type 1 diabetes” (^[49]).

In summary, INHALE-1 demonstrated that Afrezza has a safety profile in children comparable to injectable insulin, along with ancillary benefits (convenience, satisfaction, less weight). The marginally higher HbA1c outcome with Afrezza did not meet the strict noninferiority criterion, but was relatively small (0.18% difference). MannKind and FDA evidently weighed the totality of evidence – decades of inhaled insulin data, lack of safety issues, and patient preference – to deem the benefit-risk favorable.

The FDA’s acceptance and approval likely also drew on additional studies and real-world evidence. For instance, prior pediatric pharmacokinetic work showed similar insulin exposure profiles in children as adults without unexpected toxicity, and registry data have not revealed chronic lung issues with inhaled insulin in adults. The FDA press release explicitly states that the pediatric approval was supported by “the pivotal INHALE-1 trial, along with additional safety, efficacy, and long-term exposure data from studies evaluating inhaled insulin over the past two decades” (^[6]). Taken together, the clinical evidence convinced regulators that Afrezza can be safely used in youths 6+ as an prandial insulin.

Implications for Pediatric Diabetes Care

The availability of an inhaled insulin adds a qualitatively new treatment option for children and teens with diabetes. Pediatric diabetes care is highly individualized, factoring in lifestyle, growth, psychosocial aspects and family preferences. Families emphasize flexibility and quality of life for children dealing with a demanding regimen. As MannKind CEO Dr. Michael Castagna noted, “Children and their families deserve new treatment options that fit the realities of daily life” (^[11]). He highlighted that Afrezza enables dosing “at the moment of eating, without the need for pre-meal planning”, aiding unplanned meals or snacks (a common scenario for active kids) (^[11]).

Clinical experts echo this sentiment. Many pediatric endocrinologists have long expressed interest in alternatives to needles. In market research cited by MannKind, practicing pediatric endocrinologists commented on Afrezza’s features: “The timing of dosing and not having to carb count are great features…” and “Not having to worry about counting carbs or injections every time we eat would be super helpful…” (^[50]). These statements illustrate how Afrezza could reduce the burden of rigid carb-ratio calculation. Indeed, while Seyfert and colleagues found that even with advanced pump systems optimal control is rarely achieved in youth (^[51]), Afrezza’s rapid action profile offers a different approach: instant coverage for the carbohydrate present, reducing the risk of delayed insulin action and post-meal spikes.

From a practical viewpoint, switching some doses from injections to inhalations could simplify routines. Consider an example: A 10-year-old with T1D on MDI often misses his midday bolus during school lunchtime, leading to afternoon hyperglycemia. With Afrezza, the child could carry the small inhaler to school and take a puff of insulin at lunch without needing a needle or privacy of an injection. This hypothetical scenario reflects the narrative of MannKind’s caregivers: one said, “…a simple inhalation and we get to skip the mealtime routine? Great!” (^[12]). Parents also appreciate that a non-injection dose can avoid negative emotional associations of needles (^[12]).

There are also specific clinical niche considerations. Adolescents who are needle-phobic, or children on growth hormone (who are already injection-burdened), may especially welcome an inhaled option. Some children with erratic eating patterns could benefit from flexible dosing at meal onset. Additionally, some pediatric T2D patients on basal insulin might use inhaled mealtime insulin to avoid multiple injections (though only ~2% of INHALE-1 participants had T2D (^[7]), in real life this population is small but clinically important given the aggressive course of youth T2D (^[17])).

However, the new option comes with important caveats. First, Afrezza must be used with a long-acting basal insulin in T1D; it is not a full replacement for basal needs (^[52]). It is intended as a prandial supplement. Second, suitability is limited by lung status: children with asthma/COPD or even heavy current smoking (common controversy) are excluded (^[41]). In practice, many pediatric endocrinologists will test lung function (spirometry) prior to prescribing, similar to guidelines for adults (^[41]). This screening step may limit uptake in some settings without easy pulmonary lab access. Third, Afrezza’s glucose-lowering effect is meal-related, which means omitting a snack or eating late requires planning; unlike a pump, it cannot automatically deliver insulin. Families must still learn to estimate carbohydrate content or use bolus calculators for dosing. Importantly, Afrezza’s label advises that it should be inhaled “within 20 minutes after starting a meal” or at meal start (^[53]), reflecting some flexibility but requiring patient education.

Cost and coverage could be a barrier. Inhaled insulin is patented and currently more expensive per dose than off-patent injectable insulin units. Payers may demand justification against cheaper analogs or pump alternatives. The high price of Exubera (a major reason for its demise (^[29])) underscores this challenge. It remains to be seen how insurers will cover Afrezza for children; robust evidence of adherence or quality-of-life benefit may be needed to support reimbursement. Legislatively and policy-wise, Afrezza’s pediatric approval may spur discussions on formulary guidance and pediatric insulins pricing.

Overall, the approval expands the therapeutic landscape. As MannKind points out, the American Diabetes Association’s Standards of Care now list inhaled insulin as an option alongside multiple daily injections (MDI) and insulin pumps (^[10]). This formal inclusion signals to clinicians that inhaled insulin is a recognized part of evidence-based pediatric diabetes care. Over time, practice patterns may adapt: some providers may begin prescribing Afrezza to appropriate kids, integrating it with CGM data to optimally dose meals. Others may remain cautious, waiting to see real-world outcomes.

Pediatric Diabetes Devices and Market Dynamics

The pediatric diabetes device market encompasses tools for insulin delivery and glucose monitoring for children. This includes insulin pumps (tubed or tubeless), insulin pens and syringes, and glucose monitoring technologies (CGM and bloodglucose meters). The global pediatric diabetes management market – covering devices, supplies, and diagnostics – was estimated at $5.59 billion in 2024 (^[13]) and is projected to reach $13.11 billion by 2033 (CAGR ~9.96%) (^[13]). North America dominates this market (40.7% share in 2024 (^[54])), with the U.S. alone constituting roughly 36% of global pediatric diabetes revenue (88.8% of North America) (^[54]).

Within this market, continuous glucose monitors (CGMs) hold the largest segment share (~34% in 2024) (^[14]), reflecting the rapid adoption of real-time monitoring to improve glycemic control. The CGM market has been driven by technical innovation (e.g. factory calibration, smaller sensors) and approval for very young ages (Dexcom G7 for age ≥2 (^[24])). The insulin pump market is also growing, catalyzed by closed-loop systems improving outcomes. In 2024, insulin pumps and pens together comprise the remaining share; reports emphasize that insulin pumps in particular are on a growth trajectory due to user-friendly designs (tubeless pods, smartphone-controlled) and automation algorithms (^[55]) (^[25]). Advanced features for children (half-unit dosing pens, graphical apps, smaller needle gauges) are progressively introduced (^[24]) (^[56]).

Table 2 summarizes key market statistics and forecasts from recent analysis:

Table 2. Market size and segment shares in pediatric diabetes management (2024) (^[13]) (^[57]).

These figures illustrate a rapidly growing market, underpinned by rising pediatric diabetes prevalence and technology uptake. In the U.S., nearly all T1D children now have access to CGM, and pump penetration is high (over 60% in some pediatric centers). Innovations continue: e.g. Dexcom’s G7 CGM was approved in 2022 for children ≥2 (^[24]), Tandem’s mini-Mobi pump got FDA clearance in 2023 for kids ≥6 (^[25]), and Omnipod’s tubeless AID system reached younger age brackets. Beyond devices, software and telemedicine services are increasingly integrated into pediatric diabetes care as well.

MannKind’s Afrezza enters this landscape as a drug-device combination: a branded inhalation powder with a proprietary inhaler. It will be marketed under their current sales channel (likely leveraging specialist diabetes providers). Within the pediatric market, Afrezza competes in a novel category. It does not directly compete with CGMs (since it's insulin), but it competes indirectly with other prandial insulin options (injection, pump bolus). One analysis of the inhaled insulin market estimated it at $609 million in 2024 and forecast growth to ~$2.6 billion by 2034 (15.6% CAGR) (^[53]). Notably, adults with type 2 made up ~57% of that inhaled insulin market in 2024 (^[58]). The pediatric component of inhaled insulin is expected to emerge only now. Market research explicitly identifies “expansion into pediatric use” as a key trend, citing Afrezza’s INHALE-1 results as pivotal (^[5]). In essence, Afrezza’s label expansion could significantly boost its addressable market; marketing analyses by MannKind project pediatric Afrezza sales of over $200 million annually at modest uptake (^[15]).

Competition for mealtime insulin in pediatrics remains brisk. For injections, major companies (Lilly, Novo Nordisk, Sanofi) dominate analog insulins (Humalog®/Admelog®, Novolog®/Fiasp®, Apidra®, etc.). They manufacture pens and pump reservoirs. As Afrezza has no direct analog competitor (currently only Afrezza is inhaled), it may carve out an independent niche. However, any shift from injections or pump boluses represents lost business for those manufacturers. It is likely that payers and clinicians will carefully evaluate which children benefit most from Afrezza rather than view it as a blanket switch for all.

A further factor is caregiver and patient preference. Surveys indicate many families value the principle of needle-free insulin. For example, in MannKind’s research slide, a parent of a T1D child said “Not having to worry about counting carbs or injections every time we eat would be super helpful” (^[59]). These qualitative insights suggest a potential early adopters’ base among those seeking to improve the daily burden of management. On the other hand, pediatric diabetes advocates caution that inhaled insulin is not a panacea; it adds one more device (though small) to manage and still requires attention to dosing.

The pediatric diabetes device market is also influenced by regulatory changes and public programs. Governments and health organizations are pushing for improved pediatric endocrinology care, including access to advanced devices (reflected in the rapidly rising market size (^[13])). If Afrezza adoption leads to measurably better adherence or outcomes (which future studies must show), it could affect guidelines and reimbursement. Conversely, if uptake is low, its impact on the market will be modest.

We anticipate several market effects:

• Revenue potential for MannKind: By capturing even a portion of the pediatric market, MannKind could see a significant new revenue stream. If 10% of eligible pediatric patients used Afrezza, MannKind projects about $150M annually (^[15]). Given the global pediatric T1D population (~130,000 in US [assuming 0.125% prevalence of ~330 million] plus growing), even a 5–10% penetration could mean tens of thousands of units.
• Effects on competitors: Rapid-acting insulin analog sales to pediatric patients may dip modestly. However, pump manufacturers (Medtronic, Tandem, Insulet) may be less affected; in [32] MannKind estimated only 14% of pump users might switch. Insulin pump use confers other advantages (automated basal), so an inhaler voluntarily replacing a pump bolus would usually indicate dissatisfaction with pumps, not general.
• Encouragement of innovation: The success of a pediatric Afrezza could spur other companies to invest in non-invasive insulin delivery (for example, Oramed’s oral insulin capsule, or new inhalers). Regulatory willingness to approve such innovations in kids may increase.
• Whole-patient approach: Diabetes device companies increasingly package ecosystems. Dexcom and Omnipod have interoperable partnerships; Tandem’s pump ties to its app. If Afrezza could interface digitally (e.g. with tracking apps), this might be a future angle for integrated care. Currently, Afrezza inhalers log doses manually, but connected inhalers could emerge.

Case Scenarios and Patient Perspectives

To illustrate how Afrezza might be used in practice, consider two hypothetical scenarios:

• Case 1: School-Age Child with T1D and Needle Fear. Emily, an 8-year-old with T1D on MDI, dreads every fingerstick and injection. Her mother reports Emily often forgets her midday insulin doodles at school, leading to afternoon highs. After introduction of Afrezza, Emily is equipped with an inhaler and half-unit cartridges. At lunch, Emily inhales the prescribed dose without pain. She enjoys snacks freely with minor disbelief that no needle was involved. Over three months, Emily’s afternoon glucose variability decreases, and her hemoglobin A1c improves fractionally. Her mom says it has “upended” how they feel about mealtime insulin. Emily still requires basal injections at bedtime, but her mental burden is greatly eased. (This mirrors feedback like “a simple inhalation and we get to skip the mealtime routine…Great!” (^[12]).)

• Case 2: Teenager with T1D and High Activity Level. Jayden, age 14, is active in sports and social events. He uses an insulin pump for basal needs but struggles with pumping in active situations. For meals, he dislikes pumping during lunch because it exposes his condition to peers, and sometimes he omits boluses. With Afrezza, Jayden switches meal boluses to the inhaler. He can quietly take a dose and immediately return to play basketball. His CGM graph shows fewer uncorrected highs after games. His endocrinologist observes that Jayden’s weight stabilized (consistent with study findings of less weight gain on Afrezza (^[47])) and no pump site inflammation. Jayden reports feeling more normal and less self-conscious at school meals.

These scenarios highlight Afrezza’s advantages: ease of use, discretion, and flexibility. However, processing these benefits requires training. Early-adopter clinicians will need to counsel families on how to convert carbohydrate grams to cartridge doses, similar to pen dosing. They will also emphasize lung function monitoring. Importantly, neither case abandons basal insulin: Afrezza is strictly for mealtime coverage, so a basal remains essential. Families must understand that Afrezza cannot handle all of an insulin regimen; it supplements basal or pump therapy.

Family surveys before approval hinted at this appetite. On MannKind’s slides, caregivers stated: “I would definitely offer [Afrezza] as an option to my pediatric patients [if and when approved]…” (^[60]). One father noted that not counting every carb with precise injections would “really help my kid” in social settings (^[59]). Healthcare professionals also project significant interest: MannKind’s analysis shows a high willingness among pediatric endocrinologists to incorporate Afrezza into practice, as reflected in their adoption modeling (28% of MDI users, 14% of AID/pump users) (^[16]).

Nonetheless, these perspectives are balanced by caution. Endocrinology guidelines still emphasize that choices are personalized. For some families, insulin pump therapy or even upcoming fully closed-loop systems may remain preferable to manage mealtime dosing. Others might worry about pulmonary side effects, despite reassuring trial data. Some families on tight budgets may find Afrezza’s cost prohibitive if not fully covered. Therefore, the real-world adoption will likely vary: we may see pockets of high use (for example, in pediatric diabetes centers where both physicians and patients are highly engaged) and slower uptake elsewhere.

Discussion and Future Directions

The Afrezza pediatric label expansion represents both a culmination of long-term research and a starting point for future developments. From a clinical perspective, it underscores the FDA’s interest in diversifying diabetes treatments for youth. It also highlights ongoing innovation in drug delivery technology. MannKind’s CEO invoked the memory of company founder Al Mann, who had championed Technosphere technology, to emphasize the achievement (^[11]).

Looking forward, several avenues merit discussion:

• Further research in younger children. The INHALE-1 trial included children as young as 4, but the FDA approval is limited to age 6+. (The sBLA was for 4–17 (^[61]), but FDA left a two-year gap.) It is plausible that with additional data or phased trials, Afrezza could be studied down to age 4. However, very young children have smaller airways and different pulmonary pharmacokinetics; caution is warranted. Future pediatric studies may explore efficacy and safety in the 4–5 age group, though regulatory approval for that subgroup is likely a few years out at best.

• Long-term outcomes. The INHALE-1 extension provides one year of data, but the chronic use of inhaled insulin (in adults, only two-year data exist). Questions remain about lung function beyond childhood growth, and whether 10+ years of Afrezza use has any late effects. A long-term registry or post-market surveillance will be critical, particularly since children will potentially use it for decades.

• Integration with CGM and AID systems. The pediatric diabetes care model is moving toward systems-based management. Afrezza could be integrated strategically: for instance, CGM data might be used to adjust Afrezza dosing (though currently Afrezza is used like a “fast insulin” in pumps). One could imagine algorithms or apps guiding inhalation dose based on CGM trend arrows. Moreover, future hybrid closed-loop systems might include an inhalation component. A “closed-loop inhaler” concept (where a device automatically puffs insulin based on meal announcement and sensor data) is technically challenging but intriguing. For now, Afrezza remains a manual adjunct.

• Competition from other novel insulins. Beyond technology, new pharmacological products are in development. For example, former trials have looked at once-weekly insulin or glucose-responsive “smart insulin.” While those are still years away and unlikely targeted at mealtime control, any improvement in insulin pharmacology could shift pediatric choices. However, for the immediate term, Afrezza holds a unique niche as needle-free prandial insulin.

• Educational needs. Pediatric diabetes care providers (endocrinologists, diabetes educators, school nurses) will need training on Afrezza. Reliable inhaler technique (ensuring a deep lung breath), dose titration, and recognition of inhaled-specific warnings are new elements in care. ADA/other organizations may develop clinical guidelines or consensus statements on inhaled insulin use in children. Early adopters will publish their own clinical “tricks and tips” (for instance, how to handle a missed inhalation or manage cough side effects in a frightened child).

• Global perspective. In some countries, injectable insulin is already a challenge due to supply issues or reuse of syringes. Inhaled insulin could potentially reduce needle waste and sharps injuries, a win for low-resource settings. MannKind has previously sought approvals of Afrezza in India and other markets; pediatric approvals may follow. Market uptake in developing markets will depend on regulatory approvals and cost in those regions.

• Pediatric T2D considerations. An emerging concern is whether Afrezza will be used for youth-onset type 2 diabetes, a field where few oral and injectable options exist. Technosphere insulin is indicated for T2 in adults. In youth, T2D often requires insulin when oral agents fail. If a child with T2D is started on basal insulin, Afrezza could cover meals instead of analog injections. Given the aggressive nature of pediatric T2D (often higher rates of early complications (^[62])), it remains to be seen if inhaled insulin will be embraced or studied in this subgroup. Currently, INHALE-1 had very few T2 patients (2%), so evidence in that group is minimal.

• Market dynamics and pricing. On the commercial side, Afrezza will now likely be included in major pediatric formulary discussions. Its price and coverage will determine how many families can access it. If insurers require authorization, real-world usage may lag until clinician advocacy and outcomes data build the case. In parallel, competitor insulin makers will watch closely. It is conceivable that other manufacturers might develop their own inhaled formulations – though Afrezza’s patent and the difficulty of inhaled drug development are barriers. For now, Afrezza stands alone in the inhaled category.

• Psychosocial impact measurement. Beyond glycemic metrics, adoption of inhaled insulin might have measurable effects on children’s quality of life and psychological well-being. Future studies should quantitatively assess whether Afrezza users experience less diabetes distress, needle anxiety, or better adherence. Such data could further justify the value of inhaled insulin for pediatric populations. MannKind already quoted caregivers and doctors describing life improvements (^[36]); academic studies (perhaps evaluating Diabetes Quality of Life questionnaires pre- and post-switch) would strengthen understanding.

In sum, the Afrezza pediatric approval is a milestone that opens new possibilities. It will be important to monitor its real-world uptake and outcomes. If many families adopt it and report ease of living, inhaled insulin could spur a paradigm shift. On the other hand, if use remains niche, it may serve only a subset of children who truly benefit. Regardless, the approval signals progress: for the first time in over a century of pediatric insulin therapy, there is now a noninjection mealtime insulin option for children. It is a testament to multi-decade innovation and to the responsiveness of regulators to children’s unique needs.

Conclusion

In May 2026, the FDA’s approval of Afrezza for children (6+ years) with diabetes represented a landmark in pediatric diabetes management. It provides the first inhaled bolus insulin option for youth, supported by trial data showing comparable safety to injections and added benefits in satisfaction and weight control (^[47]). The approval fulfills FDA’s Pediatric Research Equity Act plans and brings inhaled insulin into ADA guidelines for children (^[10]).

This milestone has broad implications. For patients, it offers a new choice to make diabetes care easier – especially for needle-averse children or those with unpredictable lives. For clinicians, it means an additional tool to tailor therapy and potentially improve adherence. For the diabetes device market, it adds a novel category that may accelerate innovation and competition. Its commercial success will depend on caregiver acceptance, insurance coverage, and real-world outcomes.

While Afrezza will not replace pumps or eliminate the need for basal insulin, it enriches the therapeutic toolkit. It underscores the principle that pediatric care should not simply mimic adult care; children “need new treatment options that fit the realities of daily life” (^[11]).

Ongoing research and observation will be essential. Registries and post-marketing studies should track lung safety and long-term efficacy in children. Trial data may expand to younger ages or refine dosing. In parallel, technological synergy (perhaps with CGM-linked dosing algorithms) could optimize inhaled insulin’s use.

In conclusion, the Afrezza pediatric label expansion is a “step forward” in diabetes care for children (^[63]). It blends historical innovation (the technology brewing for decades) with forward-looking clinical practice. As this option becomes incorporated into standard care, its real-world impact will solidify – on health outcomes, quality of life, and the evolving landscape of pediatric diabetes devices. Future work should quantify those impacts and continue exploring ways to make insulin therapy ever more physiological and less burdensome for the youngest patients.